By attaching specialised molecules to the backbone of DNA, researchers have made it easier to detect rare molecules associated with early disease.
The presence of, or changes in the concentration of, certain proteins in biological fluids can be indicators of disease. However, in the early stages of disease these ‘biomarkers’ can be difficult to detect, as they are relatively rare.
We have now shown that this is possible to perform such measurements in real human samples, opening up the potential for meaningful early diagnosis.
– Dr Alex Ivanov
Detecting important biomarkers in lower concentrations will allow patients to be treated earlier for diseases such as some cancers and neurological disorders, which could increase the chance of survival rate.
However, current methods of detection are often not sufficiently sensitive and require costly and time-consuming sample pre-treatment.
Now, researchers from the Department of Chemistry at Imperial College London have come up with a system that is specific, flexible, and can detect single protein biomarkers directly in human serum (a pool of fluid separated from blood).
The system represents a significant innovation, as it is more sensitive to specific biomarkers and does not require clinical sample preparation. The method is published in Nature Communications.
Dr Alex Ivanov, co-leader of this study from the Department of Chemistry at Imperial, said: “The detection of single molecules of biomarkers represents the ultimate in sensitivity for early diagnosis. We have now shown that this is possible to perform such measurements in real human samples, opening up the potential for meaningful early diagnosis.”
Binding to biomarkers
The method the team developed uses the ‘backbone’ of DNA, the structure it is built around. They grafted ‘aptamers’ – synthetic DNA molecules that bind to specific target biomarkers – to DNA backbones.
When added to human serum, the aptamers bind to biomarkers before being analysed by passing through a nanopore detector. Nanopores are miniscule holes (often as small as a few billionths of a meter) that measure a change in electrical current as molecules pass through them.
Each biomarker has a unique current signature, so the presence and concentration of target biomarkers can be analysed in this way.
With the rapid growth in nanotechnology and nanopore technology, this innovative platform could pave the way for the next wave of clinical applications.
– Dr Jasmine Sze
The team demonstrated that their system can work by testing three aptamers on one DNA backbone. They found that the nanopores can detect the specific biomarkers that the aptamers were designed to pick up.
They say that the system can be constructed with more than five different aptamers, allowing detection of multiple biomarkers at once. In addition, the biomarkers were detected in human serum, meaning far less preparation time and cost were needed.
Based on the preliminary findings of this study, research efforts are now focused on several types of cancer and neurological disorders, which can benefit from the detection of biomarkers that are in low abundance in clinical samples.
The team have filed a patent for the technology, and are currently exploring routes towards commercialisation so that it can be used to ultimately improve quality of life.
Dr Jasmine Sze, who completed this study as part of her PhD in the Department of Chemistry and has recently moved to the IMED Biotech at AstraZeneca said “Looking forward, with the rapid growth in nanotechnology and nanopore technology, this innovative platform could pave the way for the next wave of clinical applications.
“It has great potential for biomarker discovery, development of companion diagnostics as well as clinical endeavours, such as direct diagnosis, prognosis and sub-type classification with single-molecule sensitivity.”
The Latest on: Disease diagnosis
- 8 Must-Meet TikTokkers Who Post on Crohn’s Diseaseon November 27, 2020 at 3:22 pm
These young people—including a dancing doctor!—have fun and crush stigmas as they educate others on life with an IBD.
- U.S. counts 13M Covid-19 cases, its fourth million-milestone of Novemberon November 27, 2020 at 2:58 pm
U.S. counts 13M Covid-19 cases, its fourth million-milestone of November The U.S. reached 13 million diagnosed cases of Covid-19 on Friday, another milestone in a month riddled with them. It was the ...
- Human brain cells could be gene-edited to reduce the risk of developing Alzheimer's disease, scientists claimon November 27, 2020 at 9:15 am
Researchers from Laval University in Canada have been working with a variant of a gene thought to make people less likely to develop Alzheimer's and live longer.
- Covid is masking the symptoms of deadliest cancer in UK – the 10 signs you must never ignoreon November 27, 2020 at 5:10 am
COVID-19 is masking the symptoms of the deadliest cancer in UK, experts say. Lung cancer, which kills more than 35,300 Brits a year, has very similar characteristics to the coronavirus. The most ...
- 'Our time with her is running out': Parents of woman, 28, in care home with rare degenerative disease calls on Boris Johnson to urgently roll-out rapid testing as her condition ...on November 27, 2020 at 4:39 am
Marian and Tom Clancy, from Stanmore, north west London, have been separated from their daughter Charlotte for nearly the entirety of both lockdowns ...
- Viral Disease Diagnosis Market Size by Regional Production Volume, Consumption Volume, Revenue and Growth Rate to 2026on November 26, 2020 at 5:46 am
Final Report will add the analysis of the impact of COVID-19 on this industry." Global Viral Disease Diagnosis Market ...
- Quantum nanodiamonds may help detect disease earlieron November 25, 2020 at 9:54 am
The quantum sensing abilities of nanodiamonds can be used to improve the sensitivity of paper-based diagnostic tests, potentially allowing for earlier detection of diseases such as HIV, according to a ...
- Co-founder of ‘ice-bucket challenge’ dies at 37 of Lou Gehrig’s diseaseon November 24, 2020 at 11:17 pm
Pat Quinn was diagnosed with Lou Gehrig’s disease, also known as amyotrophic lateral sclerosis, in 2013, a month after his 30th birthday, the ...
- NASCAR legend Morgan Shepherd diagnosed with Parkinson's diseaseon November 24, 2020 at 5:29 pm
NASCAR driver owner Morgan Shepherd has been diagnosed with early stage Parkinson's disease. The 79-year-old plans to return to the series as a car owner next year.
- Morgan Shepherd diagnosed with Parkinson’s diseaseon November 23, 2020 at 3:27 pm
We all have had challenges to overcome and Morgan has always wanted to be an encourager, defying his age in physical and mental ability. Morgan’s charity work with the physic ...
via Google News and Bing News